CLINICO-EPIDEMIOLOGICAL FEATURES OF ADULT T-CELL LEUKEMIA/LYMPHOMA (ATLL) IN JAPAN: RELATIONS OF HTLV-I/ATLV INFECTION TO ATLL MANIFESTATION

Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

CLINICO-EPIDEMIOLOGICAL FEATURES OF ADULT T-CELL LEUKEMIA/LYMPHOMA (ATLL) IN JAPAN: RELATIONS OF HTLV-I/ATLV INFECTION TO ATLL MANIFESTATION

Dev Oncol; 31:72-85 1985. Unique Identifier : AIDSLINE ICDB/86624705
Tajima K; Tominaga S; Aichi Cancer Center, Chikusa-Ku, Nagoya, Japan

Abstract: Clinico-pathological and epidemiological findings of adult T-cell leukemia/lymphoma (ATLL) in Japan are reviewed, and the epidemiological aspects of the relationship between human T-cell leukemia virus (HTLV) infection and the ATLL manifestation in the Kyushu district are discussed. HTLV carriers and patients with ATLL were primarily distributed in limited zones in Japan. Besides geographical clustering, an intrafamilial aggregation of HTLV carriers was observed as seen in ATLL cases. The frequency of HTLV carriers increases with age, especially in females. HTLV is naturally transmitted from mother to child vertically or horizontally and from husband to wife horizontally. Other than natural transmission, HTLV is transmitted by whole-blood transfusion from carrier-donor to noncarrier-recipient. It was estimated that the number of HTLV carriers was 500,000-600,000 and that the annual incidence of ATLL was 350 in the Kyushu district. The estimated incidence rate of ATLL among 1,000 HTLV carriers over age 40 was 1.4 in males and 0.5 in females. It was suggested that the average latent time of ATLL was 40-50 yr after HTLV infection in a critical age range, possibly in childhood or more early stage. In order to clarify the epidemiological evidence in more detail and to conduct plans for prevention of ATLL, a vast epidemiological study on risk factors for HTLV infection and ATLL manifestation is underway. (31 Refs)

Keywords: Adult Age Factors Antibodies, Viral/ANALYSIS Blood Donors Carrier State Disease Reservoirs Female Human HTLV-BLV Viruses/IMMUNOLOGY Japan Leukemia/*DIAGNOSIS/EPIDEMIOLOGY/TRANSMISSION Lymphoma/*DIAGNOSIS/EPIDEMIOLOGY/TRANSMISSION Male Middle Age Retroviridae Infections/*DIAGNOSIS/EPIDEMIOLOGY/TRANSMISSION Risk T-Lymphocytes Time Factors MEETING PAPER

861130
M86B0239

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .